Evidence map›Paper›PMID 41673353›Full record

ArticlePulmonary therapy2026

A Pragmatic RCT of FF/UMEC/VI in Patients with Uncontrolled Asthma: PERFORM Protocol.

Stephen G Noorduyn, Nicola Brown, Jodie Crawford, Lydia Demetriou, Afisi S Ismaila, Lawrence Mbuagbaw, Sameer Parpia, Behnam Sadeghirad, David Slade, Alison C Moore

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pulmonary therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Stephen G NoorduynDepartment of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada. stephen.g.noorduyn@gsk.com.ORCID http://orcid.org/0000-0002-5936-5579
Nicola BrownClinical Research and Early Programs, GSK, London, UK.
Jodie CrawfordDevelopment Biostatistics, GSK, London, UK.
Lydia DemetriouGSK, Stevenage, UK.ORCID http://orcid.org/0009-0004-4665-279X
Afisi S IsmailaDepartment of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.ORCID http://orcid.org/0000-0002-2876-8308
Lawrence MbuagbawDepartment of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.ORCID http://orcid.org/0000-0001-5855-5461
Sameer ParpiaDepartment of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.ORCID http://orcid.org/0000-0002-9407-5622
Behnam SadeghiradDepartment of Anesthesia, McMaster University, Hamilton, ON, Canada.ORCID http://orcid.org/0000-0001-9422-5232
David SladeRespiratory Clinical Research Unit, GSK, Collegeville, PA, USA.
Alison C MooreGlobal Medical Affairs, GSK, London, UK.

Funding

Wellcome Trust 219912
6 · The paper itself

Abstract

introductionAsthma imposes a high disease burden, with approximately half of patients experiencing uncontrolled disease despite inhaled corticosteroid/long-acting β

methodsPERFORM is a 52-week, stratified, randomised, open-label, active-controlled, parallel-group, global pragmatic trial enrolling adult patients with uncontrolled asthma, currently untreated or treated with ICS or ICS/LABA therapy. Patients will be randomised 1:1 to either initiate once-daily FF/UMEC/VI (intervention) or continue or initiate non-ELLIPTA ICS/LABA (control), receiving treatment in a usual care setting. The primary endpoint is the change from baseline in trough forced expiratory volume in 1 s at week 24. The key secondary endpoint is whether patients achieve improvement (≥ 0.5-point decrease from baseline) in the Asthma Control Questionnaire-7 score at week 24. Other secondary endpoints include clinical remission, health-related quality of life, and work and activity impairment. The trial aims to randomise 1136 patients (568 per arm). PLANNED OUTCOMES: PERFORM is a pragmatic randomised controlled trial generating data relevant to a broad population of patients with uncontrolled asthma representative of routine clinical practice. This trial will also include the first prospective data on clinical remission for patients treated with inhaled therapy.

Indexed as

Asthma controlClinical remissionFF/UMEC/VIInhaled therapyLung functionRandomised pragmatic effectiveness trialReal-worldStudy protocol

Identifiers

PMID41673353
PMCPMC12992862

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.